Symptom-centric view
Off label use
Substances reporting Off label use disproportionately — ranked by ROR.
showing 7 of 7
| Substance ↓ | ROR [95% CI] | Reports | Category | Label |
|---|---|---|---|---|
tretinoin Retin-A · Atralin | 2.9 [2.7–3.1] | 946 | injectables | new |
semaglutide Ozempic · Wegovy | 2.3 [2.2–2.3] | 7,322 | glp-1 | new |
nicotinamide Niacinamide | 9.9 [9.1–10.8] | 716 | longevity | new |
| 2.4 [2.3–2.4] | 22,386 | algemeen | new | |
| 3.1 [2.9–3.3] | 1,620 | algemeen | new | |
| 2.4 [2.3–2.4] | 22,400 | algemeen | new | |
| 2.3 [2.2–2.3] | 11,950 | algemeen | new |
ROR = reporting odds ratio vs. the full FAERS corpus. A signal is not a cause. Source: openFDA (FAERS).